Upcoming Milestones as follows:Two Phase Ib clinical trials of...

Upcoming Milestones as follows:

Two Phase Ib clinical trials of BNC210 are anticipated to commence next quarter (quarter 3 2010). The first of the new trials will evaluate BNC210 effects when anxiety is induced in healthy subjects whilst the second trial will evaluate BNC210 effects on the brain using electroencephalograph (EEG) measurements. The trials will continue to look at whether side effects such as sedation or memory impairment, are associated with the administration of BNC210.

Also possibility of Interim Phase II clinical data for Renal Cancer. Mesothelioma Interim data Q1 2011.

Next six months or so should be interesting with potential for partnering on the back of these results